The GLP-1 agonists used were liraglutide (57.3%), followed by semaglutide (32.9%), dulaglutide (4.9%), exenatide (4.1%), and lixisenatide (0.9%)
Designed to inhibit DPP-4, the enzyme found to degrade GLP-1 (7-37), this drug, generically called sitagliptin, was developed at Merck by its first research team solely led by women
Compounded Prescriptions vs
Injections are given once per week, and your practitioner will normally start you at a lower dose, gradually increasing it as theyre able to monitor its effects and your progress
Regular review appointments during the first few months of GLP-1 treatment are advisable for patients with pre-existing IBS to ensure both conditions are optimally managed and to maintain quality of life
Some patients use occasional standalone infusions before or after long-haul travel, demanding work periods, weddings or events